BEAM regimen

chemotherapy protocol consisting of the above cpds; mini-BEAM used for treatment of Hodgkin's and non-Hodgkin's lymphoma

Also Known As:

mini-BEAM protocol; mini-BEAM salvage protocol

Networked: 42 relevant articles (7 outcomes, 7 trials/studies)

Relationship Network

Therapy Context: Research Results

Therapeutics: 1158551
- Drug Therapy: 293145
  - Combination Drug Therapy: 12066
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - BEAM regimen: 42
  - Antineoplastic Protocols: 55
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - BEAM regimen: 42
- Clinical Protocols
  - Antineoplastic Protocols: 55
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - BEAM regimen: 42
Organic Chemicals: 133
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - Pyrimidine Nucleosides: 50
      - Cytidine: 535
        Cytarabine: 6662
        BEAM regimen: 42
Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleosides: 6847
  - Pyrimidine Nucleosides: 50
    - Cytidine: 535
      - Cytarabine: 6662
        BEAM regimen: 42
  - Arabinonucleosides: 1
    - Cytarabine: 6662
      - BEAM regimen: 42
Polycyclic Compounds: 6
- Polycyclic Aromatic Hydrocarbons: 2020
  - Naphthalenes: 18
    - Tetrahydronaphthalenes: 1
      - Podophyllotoxin: 562
        Etoposide: 10706
        BEAM regimen: 42
Carbohydrates: 22023
- Glycosides: 2119
  - Glucosides: 639
    - Etoposide: 10706
      - BEAM regimen: 42
Amino Acids, Peptides, and Proteins: 1
- Amino Acids: 30675
  - Cyclic Amino Acids: 3
    - Aromatic Amino Acids: 467
      - Phenylalanine: 4090
        Melphalan: 4353
        BEAM regimen: 42

Experts

1.	Tilly, Hervé: 3 articles (11/2015 - 04/2011)
2.	Bouabdallah, Krimo: 2 articles (01/2020 - 04/2011)
3.	Bouabdallah, Reda: 2 articles (01/2020 - 12/2014)
4.	Le Gouill, Steven: 2 articles (01/2020 - 04/2011)
5.	Ribrag, Vincent: 2 articles (11/2015 - 04/2011)
6.	Ghesquières, Hervé: 2 articles (12/2014 - 04/2011)
7.	Gisselbrecht, Christian: 2 articles (12/2014 - 04/2011)
8.	Morschhauser, Franck: 2 articles (12/2014 - 04/2011)
9.	Ifthikharuddin, J J: 2 articles (07/2011 - 12/2004)
10.	Caballero, M D: 2 articles (10/2004 - 03/2004)

Related Diseases

1.	Hodgkin Disease (Hodgkin's Disease) 09/01/2006 - "Treatment options in relapsed or refractory Hodgkin disease patients: the mini-BEAM regimen does exist too." 01/01/1997 - "Eighteen patients with relapsed or refractory Hodgkin's disease (HD) have been treated with high-dose chemotherapy (BEAM regimen) followed by autologous peripheral stem cells and/or bone marrow rescue. " 03/01/1996 - "Forty-two patients with relapsed or refractory Hodgkin's disease (HD) were treated with high-dose chemotherapy (BEAM regimen) followed by autologous bone marrow and/or peripheral blood progenitor cell (PBPC) rescue. " 01/01/2021 - "Case Report: PD-1 Blockade Combined Autologous Hematopoietic Stem Cell Transplantation With Modified BEAM Regimen Containing High-Dose Cytarabine to Treat R/R Hodgkin's Lymphoma." 04/01/1995 - "We have previously demonstrated a dose response relationship in Hodgkin's disease for the combination of BCNU, VP16, Ara C and Melphalan, with the superior efficacy of the BEAM regimen requiring haemopoietic support, compared with miniBEAM. "
2.	Lymphoma (Lymphomas) 04/01/2023 - "Conclusion: Our study showed that modified BeEAM is a safe, effective, and feasible conditioning regimen for ASCT in lymphoma instead of the BEAM regimen." 12/01/2022 - "The SEAM regimen is feasible and might be an ideal alternative to BEAM regimen for lymphoma auto-SCT." 01/01/2022 - "In conclusion, we demonstrated that the BEAM regimen is an effective high-dose chemotherapy for lymphoma patients before AHSCT. " 01/01/2020 - "It leads to a drop in lung volumes but no obstruction or decrease in diffusion in patients with lymphoma receiving the BEAM regimen. " 01/01/2019 - "The R-BEAM regimen has a survival benefit in lymphoma patients age ≤ 50 years undergoing alloSCT. "
3.	Non-Hodgkin Lymphoma (Lymphosarcoma) 11/01/2012 - "A standard salvage therapy of relapsed/refractory aggressive non-Hodgkin lymphoma (NHL) comprises autologous stem cell transplantation (ASCT) after chemotherapy conditioning with carmustine, etoposide, cytarabine, and melphalan (BEAM) regimen. " 12/01/2016 - "This phase II study investigated the safety and efficacy of high-dose PG-free melphalan when included in the carmustine, etoposide, and cytarabine (BEAM) regimen for adult patients with non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL). " 11/01/1993 - "The mini-BEAM regimen (BCNU, etoposide, cytarabine, melphalan) and its modification 'Dexa-BEAM' are effective salvage protocols for relapsed Hodgkin's disease and non-Hodgkin's lymphoma. " 02/01/1995 - "After standard high-dose chemotherapy with cyclophosphamide, etoposide and BCNU (CVB regimen for patients with Hodgkin's disease) or BCNU, etoposide, cytosine arabinoside and melphalan (BEAM regimen for patients suffering from non-Hodgkin's lymphoma) followed by autologous BMT, r-metHuG-CSF was administered by continuous intravenous infusion from the first day after autologous BMT until neutrophil recovery. "
4.	B-Cell Lymphoma (Lymphoma, B Cell) 04/01/2011 - "This study was designed to evaluate the safety and efficacy of a conventional dose of yttrium-90 ((90)Y) ibritumomab tiuxetan combined with the etoposide rabinoside acytarabine melphalan (BEAM) regimen before autologous stem cell transplantation (ASCT) in chemosensitive relapsed or refractory low-grade B-cell lymphomas. "
5.	Pathologic Complete Response 12/01/2000 - "Patients in complete remission after induction received one course of intensification with stem cell support (BEAM regimen), whereas patients in partial response received two intensifications (BEAM, then ICE regimens). " 12/01/2014 - "Seventy-five high-risk (≥2 International Prognostic Index [IPI] factors) consecutive DLBCL patients (≤65 years old) in complete remission (CR) or partial remission (PR) after rituximab chemotherapy were treated with Y(90) ibritumomab tiuxetan and BEAM regimen followed by autologous stem cell transplantation (ASCT). "

Related Drugs and Biologics

1.	Etoposide (VP 16)
2.	Melphalan (Alkeran)
3.	Carmustine (FIVB)
4.	Cytarabine (Cytosar-U)
5.	ibritumomab tiuxetan (Zevalin)
6.	Yttrium-90
7.	Antilymphocyte Serum (Anti-Thymocyte Globulin)
8.	Rituximab (Mabthera)
9.	Amifostine (Ethyol)
10.	Bendamustine Hydrochloride

Related Therapies and Procedures

1.	Stem Cell Transplantation
2.	Drug Therapy (Chemotherapy)
3.	Autologous Transplantation
4.	Transplantation
5.	Hematopoietic Stem Cell Transplantation